Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV7TMB)

• Drug Name: Benzimidazole derivative 6 Drug Info
• Synonyms: PMID28270010-Compound-Figure7-1

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Patented	[1]

• Cross-matching ID:
  PubChem CID: 57345941
  CAS Number: CAS 1357920-84-3
  TTD Drug ID: DMV7TMB

Molecule-Related Drug Atlas

Drug(s) Targeting Tropomyosin-related kinase A (TrkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[2]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[3]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
MIM-D3	DMZHN5B	Alzheimer disease	8A20	Phase 3	[5]
SNA-120	DMPN314	Plaque psoriasis	EA90.0	Phase 2	[6]
CT 327	DMQXL1T	Plaque psoriasis	EA90.0	Phase 2	[7]
ONO-7579	DMXLPYE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[8]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]

Drug(s) Targeting ALK tyrosine kinase receptor (ALK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[10]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[2]
Brigatinib	DM7W94S	Anaplastic large cell lymphoma	2A90.A	Approved	[11]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[3]
Ceritinib	DMB920Z	Non-small-cell lung cancer	2C25.Y	Approved	[12]
Alectinib	DMP1I6Y	Lung cancer	2C25.0	Approved	[13]
Ensartinib	DMIKDCQ	Non-small-cell lung cancer	2C25.Y	Phase 3	[3]
PF-06463922	DMKM7EW	Non-small-cell lung cancer	2C25.Y	Phase 2	[14]
AP26113	DMYBQEF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ALK tyrosine kinase receptor (ALK)	TTPMQSO	ALK_HUMAN	Inhibitor	[1]
Tropomyosin-related kinase A (TrkA)	TTTDVOJ	NTRK1_HUMAN	Inhibitor	[1]

References

• [1] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
• [8] National Cancer Institute Drug Dictionary (drug id 747694).
• [9] National Cancer Institute Drug Dictionary (drug id 766123).
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [11] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
• [13] CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90.
• [14] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.
• [15] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.